Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 4, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024. A corporate presentation is scheduled for 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time).
Related news for (VNDA)
- Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
- Vanda Pharmaceuticals announces the publication in PLOS One of an article titled “Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial”
- Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
- Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
- Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S